Teledermatology-Based Presurgical Management for Nonmelanoma Skin Cancer: A Pilot Study

Abstract

SFTD has been demonstrated to be effective and accurate as a preoperative tool for nonmelanoma skin cancer, avoiding unnecessary visits to the hospital and shortening the waiting intervals to the surgical treatment.

Teledermatology for diagnosis and management of skin conditions: A systematic review

“…67 Time to surgery or definitive intervention was significantly shorter in the 3 studies that reported this outcome. 9,67,68 The difference ranged from 21 to 86 days (all P \.01). Two studies reported time to teledermatology results.…”

“…Teledermatology patients required a mean of 0.98 visits in one study 67 and one visit in another study. 9 In the same two studies, clinic dermatology patients required a mean of 1.13 or at least 2 visits, respectively.…”

“…Technology assessment only. 9. Remote monitoring of known diagnoses (eg, leg ulcers, postoperative wounds).…”

“…org). 3,6,8,9,11,12,14,15,22,25,30,41,42,44,45 Two studies evaluated concordance of the triage management decision of ''refer or not refer'' for pigmented skin lesions 30 or skin lesions 12 ; percent concordance was 80% 30 and 61% 12 for these two studies yielding a weighted average of 75.3% (809/1075). Three studies (in 4 publications) evaluated concordance for the diagnostic procedure decision ''biopsy or no biopsy'' and found concordance rates of 100% 22 and 95% 42 for skin lesions (weighted average of 98.5%, 68/69) and 76% for a variety of skin conditions.…”

“…All studies used a repeated measures study design with the exception of one randomized controlled trial. 11 Based on location, most of the studies were conducted in the United States (n = 14), [3][4][5][6]22,24,25,33,35,37,[41][42][43]45 followed by the United Kingdom (n = 9), 11,12,15,18,29,30,32,38,44 Italy (n = 6), 7,8,20,21,36,39 Spain (n = 4), 9,10,13,17 Australia/New Zealand (n = 3), 14,31,40 Turkey (n = 2), 16,19 and one study each from Germany, 23 Netherlands, 24 Pakistan, 27 Brazil, 28 and Switzerland. 34 Patient and skin condition characteristics.…”